NuCana (NASDAQ:NCNA) Trading Up 5.8% – Here’s What Happened

Shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) rose 5.8% during trading on Thursday . The stock traded as high as $1.6667 and last traded at $1.63. Approximately 18,351 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 54,613 shares. The stock had previously closed at $1.54.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

NuCana Stock Performance

The firm has a market capitalization of $6.78 million, a P/E ratio of -0.01 and a beta of 1.79. The stock has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $3.31.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in NuCana stock. FNY Investment Advisers LLC raised its stake in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,000 shares of the company’s stock after acquiring an additional 6,774 shares during the quarter. FNY Investment Advisers LLC owned approximately 33.33% of NuCana worth $36,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 44.00% of the company’s stock.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.